IGF2BP2 and prostate carcinoma: It should be emphasized that various prostate cancer cells may react differently to DDIT4 mRNA that has been modified by FTO/IGF2BP2/IGF2BP3 and that although DDIT4 is believed to participate in proliferation-related signaling pathways, its regulatory mechanism is complex and there are many interfering factors.